MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
Citigroup
American investment bank and financial services corporation
Related events
- MarketBeat reported analyst ratings related to Citigroup.
- MarketBeat published average ratings and price targets for Kalaris Therapeutics, while Citigroup reaffirmed an outperform rating and TD Cowen initiated coverage with a buy rating.
- Benchmark initiated coverage with a buy rating, while MarketBeat provided consensus data and Citigroup reduced its target price.
- MarketBeat provides stock rating data for Vivos Therapeutics, which is listed on Nasdaq.
- MarketBeat aggregates data on Formula One Group, while Citigroup provides analyst ratings. Chase Carey sold company shares as a director.